Stellantis NV (NYSE: STLA) reportedly disclosed its plan to offer voluntary buyouts to 6,400 U.S. salaried employees as a part of its cost-saving initiative.
Eli Lilly And Co's (NYSE: LLY) investigational RNA-directed drug lepodisiran lowered lipoprotein(a) levels in a Phase 1 study. Elevated levels of Lp(a) have been associated with a higher risk of heart disease, heart attack, and stroke.